Meritage Portfolio Management Sells 90 Shares of Axon Enterprise, Inc $AXON

Meritage Portfolio Management reduced its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 6.0% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,410 shares of the biotechnology company’s stock after selling 90 shares during the period. Meritage Portfolio Management’s holdings in Axon Enterprise were worth $1,167,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. TCTC Holdings LLC boosted its stake in shares of Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 24 shares in the last quarter. Bartlett & CO. Wealth Management LLC boosted its stake in shares of Axon Enterprise by 132.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 33 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of Axon Enterprise in the 1st quarter valued at approximately $31,000. Catalyst Capital Advisors LLC bought a new stake in shares of Axon Enterprise during the first quarter worth $32,000. Finally, Flaharty Asset Management LLC bought a new stake in shares of Axon Enterprise during the first quarter worth $33,000. 79.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AXON. Needham & Company LLC reaffirmed a “buy” rating and set a $870.00 target price on shares of Axon Enterprise in a research note on Wednesday, September 24th. UBS Group reaffirmed a “neutral” rating and issued a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Bank of America upped their target price on Axon Enterprise from $895.00 to $1,000.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Raymond James Financial reaffirmed an “outperform” rating and issued a $855.00 target price (up previously from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a report on Tuesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $841.64.

Axon Enterprise Trading Down 4.2%

NASDAQ AXON opened at $703.03 on Monday. The business’s 50-day moving average price is $755.57 and its two-hundred day moving average price is $714.84. Axon Enterprise, Inc has a 12 month low of $422.38 and a 12 month high of $885.91. The firm has a market capitalization of $55.19 billion, a PE ratio of 173.59, a price-to-earnings-growth ratio of 27.30 and a beta of 1.41. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The business’s revenue was up 32.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insider Buying and Selling at Axon Enterprise

In related news, CAO Jennifer H. Mak sold 77 shares of Axon Enterprise stock in a transaction on Monday, September 15th. The shares were sold at an average price of $760.00, for a total transaction of $58,520.00. Following the completion of the transaction, the chief accounting officer owned 15,003 shares of the company’s stock, valued at $11,402,280. This trade represents a 0.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total transaction of $75,254.00. Following the transaction, the director directly owned 1,416 shares of the company’s stock, valued at $1,065,596.64. This represents a 6.60% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 59,932 shares of company stock worth $45,115,616. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.